fexofenadine / Generic mfg. - LARVOL DELTA

Effect of immunoglobulin-replacement therapy on the incidence of severe infections in patients with chronic lymphocytic leukemia (ASH 2025) - "HGG isassociated with a higher risk of severe infections, which are one of the major causes of morbidity andmortality in patients with CLL (Allegra et... The present real-world evidence study shows that monthly IGIV-C10% infusions are aneffective therapy in reducing the odds of severe infections in patients with CLL and HGG."

Clinical • Chronic Lymphocytic Leukemia • Chronic Obstructive Pulmonary Disease • Hematological Malignancies • Hypertension • Immunology • Infectious Disease • Leukemia • Pulmonary Disease • Respiratory Diseases

BH09 Rapid resolution of chronic spontaneous urticaria with ritlecitinib in a patient with alopecia universalis. (PubMed, Br J Dermatol) - "Initial management included high-dose fexofenadine, famotidine, montelukast and omalizumab...Pulsed dexamethasone provided modest improvement in her urticaria symptoms but did not alter the progression of her alopecia...While JAK inhibitors are not established as a standard treatment for CSU, limited case series have documented the use of tofacitinib in refractory cases...The rapid and sustained symptom resolution observed in this patient suggests the potential of ritlecitinib as a novel therapeutic option for refractory CSU. Further investigation is warranted to evaluate its broader clinical applicability and efficacy in CSU management."

Journal • Alopecia • Asthma • Chronic Spontaneous Urticaria • Dermatology • Endocrine Disorders • Immunology • Pulmonary Disease • Respiratory Diseases • Urticaria

CD12 Severe allergic contact dermatitis to jagua henna temporary tattoo. (PubMed, Br J Dermatol) - "She required treatment with a 7-day course of oral steroid, flucloxacillin and fexofenadine as it was not responding to topical steroid creams. The patch tests also showed positive reactions to balsam of Peru, fragrance mix I, hydroperoxide of linalool, and 2-n-octylisothiazolinone. We report a case of allergic contact dermatitis caused by jagua henna temporary tattoo, which highlights the presence of an emerging allergenic substance 'genipin' used in temporary tattoos."

Journal • Allergy • Contact Dermatitis • Dermatitis • Dermatology • Immunology • Oncology • Pain • Solid Tumor

Targeted LC-MS/MS method for quantifying respiratory pharmaceuticals in wastewater. (PubMed, Environ Sci (Camb)) - "Application to 12 neighborhood-level wastewater samples detected 9 of the 10 target compounds, with 6 (albuterol, amoxicillin, azithromycin, cetirizine, diphenhydramine, and fexofenadine), detected above their quantification limits. Fexofenadine was the most abundant, reaching 3309 ng L-1. This robust, low-volume, high-throughput LC-MS/MS method enables the reliable detection of respiratory pharmaceuticals in wastewater, supporting WBE applications for pharmaceutical use surveillance."

Journal • Respiratory Diseases

Efficacy of a Combination Therapy of Montelukast and Antihistamines in Allergic Rhinitis: A Systematic Review and Network Meta-Analysis. (PubMed, Allergy Asthma Immunol Res) - "The treatment strategies included montelukast alone, antihistamine monotherapies (loratadine, desloratadine, levocetirizine, and fexofenadine), their respective combinations with montelukast, including bilastine. Although some comparisons require cautious interpretation, montelukast-based combination therapy demonstrated greater efficacy than monotherapy for multiple AR symptoms. These results highlight the importance of selecting therapeutic strategies based on the predominant symptom profile of individual patients."

Journal • Retrospective data • Review • Allergic Rhinitis • Conjunctivitis • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology

Changed expression of placental transporters and disrupted epigenetic patterns in a rat model of schizophrenia. (PubMed, Front Pharmacol) - "Fexofenadine was administered per os (10 mg/kg) to pregnant rats and plasma concentrations of fexofenadine were determined with HPLC analysis on the 21 and 22 days of gestation...We hypothesize that the altered protein expression may also be a result of the disease-induced epigenetic pattern changes. This study presents novel disease-associated placental ABC transporter alterations, which highlights the dangers of using transporter substrates, especially P-gp, during pregnancy."

Journal • Preclinical • Breast Cancer • CNS Disorders • Oncology • Psychiatry • Schizophrenia • Solid Tumor

Approach to Managing Recalcitrant Alopecia Areata With Combination Therapy: A Series of Five Cases in Black Pediatric Patients (ISDS 2025) - " We present a case series of five Black pediatric patients diagnosed with moderate to severe AA, treated between 2019-2025, using topical janus kinase inhibitors (JAKi), oral fexofenadine, and vitamin D supplementation. In two of these cases, additional treatment modalities including oral upadacitinib, platelet-rich plasma (PRP), red light therapy (RLT), and excimer UVB phototherapy, were incorporated alongside the aforementioned treatment regimen... This case series contributes to existing evidence on the efficacy of JAK inhibitors (JAKi) for the treatment of pediatric AA, and supports the use of topical JAKi as a viable alternative for pediatric patients who may have contraindications to corticosteroids, immunosuppressive agents, or oral JAKi. Combination therapy with topical JAKi, vitamin D supplementation, antihistamines, and other interventions may play a crucial role in reducing active disease progression and maintenance therapy is essential in preventing relapse."

Clinical • Combination therapy • Alopecia • Dermatology • Immunology • Inflammation • Pediatrics • Psychiatry

EMPIRE-II: Investigation of the NVT ALLEGRA Plus THV System in Patients With Severe Aortic Stenosis or Failed Surgical Aortic Bioprosthesis (clinicaltrials.gov) - P=N/A | N=177 | Active, not recruiting | Sponsor: NVT GmbH | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2029 ➔ Dec 2031 | Trial primary completion date: Mar 2025 ➔ Mar 2027

Enrollment closed • Trial completion date • Trial primary completion date • Cardiovascular

EMPIRE: Investigation of the ALLEGRA THV System With a New Delivery System in Patients With Aortic Stenosis or Failed Surgical Bioprosthesis (clinicaltrials.gov) - P=N/A | N=137 | Completed | Sponsor: NVT GmbH | Active, not recruiting ➔ Completed

Trial completion • Cardiovascular

Histamine mediates food intake, but not muscle adaptations, following 10 weeks of resistance training in humans. (PubMed, J Physiol) - "Acute study: Eight men performed three resistance training sessions with intake of either placebo, H1-receptor antihistamine (180 mg fexofenadine) or combined H1/H2-receptor antihistamine (540 mg fexofenadine/40 mg famotidine). Histaminergic crosstalk in the muscle microenvironment is involved in endurance and high-intensity interval training adaptations, but this may not be a universal mechanism across all training modalities. Histamine blockade leads to increased habitual carbohydrate intake and fat mass following 10 weeks of resistance training, possibly due to histamine's role in hypothalamic appetite regulation."

Journal • Allergy • Hypotension • Immunology

Clinical Journey and Immunoglobulin-Replacement Therapy Treatment Patterns in Chronic Lymphocytic Leukemia Patients (ASH 2024) - "IgG deficiency or hypogammaglobulinemia is a subtype of SID that leads to higher risk of infections and constitutes one of the major causes of morbidity and mortality in these patients (Allegra et al...Mean (SD) time between IgRT doses was 6.1 (3.8), 9.3 (7.8) and 14.0 (14.9) weeks, respectively.Conclusions : The present real world cohort study exposes the low proportions of IgG testing and IgRT use among CLL patients with severe or recurrent infections. In addition, among patients who received IgRT, this study also seems to uncover suboptimal IgRT use with long intervals between doses."

Clinical • Chronic Lymphocytic Leukemia • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Oncology

Comparing Antihistamines for Chronic Urticaria: Systematic Review Dose Response and Network Meta-Analysis of Randomized Trials (ACAAI 2025) - "Sedation likely increases with higher doses, with first-generation agents among the most sedating; cetirizine, ketotifen, levocetirizine, and rupatadine among the intermediate sedating; and bilastine, desloratadine, fexofenadine, and loratadine among the least sedating. Cetirizine and loratadine are among the most effective for all components of urticaria activity, but cetirizine is intermediately sedating and loratadine has lower certainty on improving quality of life and sleep. Higher doses may have diminishing benefits and increased risks."

Retrospective data • Review • Anesthesia • Cardiovascular • CNS Disorders • Dermatology • Immunology • Pruritus • Sleep Disorder • Urticaria

Unmasking Splenic Marginal Zone Lymphoma Through Refractory Chronic Urticaria and Eosinophilia (ACAAI 2025) - "He was started on fexofenadine 360mg BID, famotidine 20mg QD, and referred to hematology oncology for additional evaluation...Ketotifen 1mg BID and prednisone burst was added...Omalizumab was considered, but repeat Rituximab led to rapid symptom improvement...Rituximab was effective in controlling symptoms, highlighting the potential role of B-cell targeted therapies in paraneoplastic urticaria. A multidisciplinary approach was essential in reaching the diagnosis and optimizing treatment."

Dermatology • Eosinophilia • Fatigue • Hematological Malignancies • Immunology • Lymphoma • Marginal Zone Lymphoma • Splenic Marginal Zone Lymphoma • Urticaria

More Than Just a Gut Feeling: Unmasking Systemic Mastocytosis Behind Chronic GI Symptoms (ACG 2025) - "These findings fulfilled both the major and minor diagnostic criteria for systemic mastocytosis, specifically the indolent variant.After trials with multiple medications, the patient's symptoms have been controlled with fexofenadine, montelukast, and famotidine. Other medications included Cromolyn, which was discontinued due to poor adherence, and a trial drug, Avapritinib, which was stopped due to lower extremity edema and weight gain. This case illustrates the diagnostic and therapeutic challenges of GI involvement in systemic mastocytosis...A low-histamine diet, escalated antihistamine therapy, and consideration of advanced therapies may also provide symptomatic relief and improve quality of life.Figure: Esophagogastroduodenoscopy (EGD) revealed diffuse moderate inflammation in the second portion of the duodenum, charactherized by mucosal congestion, erythema, and nodularity. Figure: Colonoscopy revealed diffuse moderate inflammation in the proximal transverse..."

Barrett Esophagus • Cardiovascular • Celiac Disease • Dermatology • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Hypertension • Immunology • Inflammation • Osteoporosis • Rare Diseases • Rheumatology • KIT

Recommendations for the management of menopausal vasomotor symptoms in clinical practice (PubMed, Semergen) - "In addition to Hormone Therapy for Menopause, scientifically supported non-hormonal alternatives are included, among them fexofenadine, which has demonstrated efficacy in clinical trials for the treatment of moderate to severe vasomotor symptoms. Taken together, these recommendations constitute an accessible and up-to-date resource for improving the care and quality of life of women in the menopausal stage."

Journal • Review

Effect of Surfactants on Oral Delivery of Nanoemulsions Containing Fexofenadine, a Substrate for P-glycoprotein. (PubMed, AAPS PharmSciTech) - "Nanoemulsions are considered to have an advantage in improving the oral bioavailability of poorly absorbed drugs. In PGFE-containing nanoemulsions, the increased bioavailability of the P-gp substrate drug was lower than PS60-containing nanoemulsions. However, data indicate that PGFE has a weaker P-gp inhibitory potential than PS60 in the cellular transport of digoxin, and it may serve as a surfactant with minimal P-gp interaction in the gastrointestinal tract when used in combination with P-gp substrate drugs."

Journal • Gastrointestinal Disorder

A Study to Evaluate the Effects of KarXT on the Drug Levels of Midazolam, Fexofenadine, and Digoxin (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: Karuna Therapeutics | Not yet recruiting ➔ Recruiting

Enrollment open

SO, I'VE HAD THIS COUGH... (CHEST 2025) - "Prior to referral, the patient's medical management included guaifenesin, fluticasone, fexofenadine, and omeprazole, leading to no improvements. DPM is a rare disorder with uncertain etiology and uncertain clinical significance. There are limited reports of associated malignancies. Currently, DPM is considered a benign disorder without a specific treatment; however, the associated chronic cough can lead to psychological and physical distress [3]."

Allergic Rhinitis • Asthma • Chronic Cough • Cough • Fibrosis • Gastroenterology • Gastroesophageal Reflux Disease • Immunology • Interstitial Lung Disease • Otorhinolaryngology • Pulmonary Disease • Rare Diseases • Respiratory Diseases

Fexofenadine protects against osteoarthritis by targeting Smad2 and STAT1 to enhance anabolism and binding cPLA2 to inhibit catabolism. (PubMed, Cell Death Discov) - "Mechanism of Fexofenadine in treating osteoarthritis. Created with BioRender.com."

Journal • Allergy • Immunology • Inflammation • Metabolic Disorders • Osteoarthritis • Pain • Rheumatology • SMAD2 • STAT1 • TGFB1

Efficacy of herbal medicine Xiao-Feng-San combined with auricular acupuncture for atopic dermatitis: A randomized controlled trial. (PubMed, Integr Med Res) - P=N/A | "Secondary outcomes included fexofenadine use, Dermatology Life Quality Index (DLQI), serum total IgE, and adverse events...Further studies should validate these results across broader populations, with post-intervention follow-up, and diverse traditional medicine regimens. ClinicalTrials.gov (NCT06492902)."

Clinical • Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation

Cytosolic phospholipase A2 as a therapeutic target for degenerative joint diseases. (PubMed, Bone Res) - "Furthermore, the therapeutic potential of fexofenadine, an over-the-counter drug recently identified as a cPLA2 inhibitor, was explored in these models...This study identifies cPLA2 as a pivotal driver of cartilage degeneration and senescence in OA and IVDD, highlighting its potential as a dual-action therapeutic target that suppresses both inflammation and senescence to preserve cartilage integrity. These findings position cPLA2 as a promising candidate for developing disease-modifying therapies for cartilage degenerative conditions such as OA and IVDD."

Journal • Immunology • Inflammation • Musculoskeletal Diseases • Osteoarthritis • Pain • Rheumatology

Evaluation of the Pharmacokinetic Interactions of Maytenus ilicifolia Mart. ex Reiss Extracts on Drug Intestinal Permeability and Hepatic Metabolism. (PubMed, ACS Omega) - "The hydroacetonic extract (HAE1) exhibited a remaining activity (%RA) of 50.1% for the 1-hydroxylation of midazolam and 40.1% for the oxidation of nifedipine, indicating moderate inhibition of CYP3A4. HAE1 reduced the fexofenadine efflux ratio to an extent similar to that of verapamil (IC50 = 20.42 μg/mL), suggesting an inhibitory effect on the P-gp activity. The extracts demonstrated the potential to inhibit both CYP3A4 and P-gp. Therefore, coadministration of M. ilicifolia-based preparations may potentially alter the pharmacokinetics of drugs that are substrates of these systems."

Journal • PK/PD data • CYP3A4

The Road to Precision Nanomedicine: An Insight on Drug Repurposing and Advances in Nanoformulations for Treatment of Cancer. (PubMed, AAPS PharmSciTech) - "This article analyzes various types of nanoparticles encapsulating different classes of drugs, such as phenelzine, fexofenadine, telmisartan, losartan, metformin, canagliflozin, atorvastatin, and fenbendazole, highlighting their anticancer effects and the influence of nanocarriers on the drug's therapeutic effect. Additionally, this review highlights the present challenges in the clinical translation of nanoformulation and demonstrates how artificial intelligence may facilitate drug screening and identification, therapeutic optimization, and large-scale manufacture. Finally, using these technologies in combination with drug repurposing presents a promising direction for advancing cancer treatment."

Journal • Review • Oncology

Omalizumab Withdrawal Protocol for Chronic Spontaneous Urticaria: Clinical Case (PubMed, Rev Alerg Mex) - "We present the case of a patient with chronic spontaneous urticaria. After achieving complete remission with omalizumab, the tapering protocol proposed by the WAO was implemented. During this period, our patient remained asymptomatic, with UCT scores greater than 13, allowing for progressive reduction of antihistamine use. The omalizumab tapering protocol for the treatment of chronic spontaneous urticaria is safe and effective, reduces the risk of disease reactivation, and prevents prolonged treatment."

Journal • Allergy • Cardiovascular • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria

Clinical overlap between Psoriasis, Atopic Dermatitis and Prurigo Nodularis. A rare phenotipic presentation (EADV 2025) - "Therapy was adjusted to include fexofenadine 180 mg daily, methotrexate 20 mg weekly, and continued guselkumab...At the one-year mark, guselkumab was discontinued due to lack of efficacy, and treatment was switched to ixekizumab 80mg monthly... The Flip Flop phenomenon was described between psoriasis and atopic dermatitis. This case shows how prurigo nodularis and AD can both be also part of the phenomenon. It underscores the importance of careful clinical evaluation, individualized treatment strategies, and vigilance for systemic complications, especially in patients receiving long-term target therapy."

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Infectious Disease • Nephrology • Prurigo Nodularis • Pruritus • Psoriasis • Respiratory Diseases • Tuberculosis